- Home
- SES vs TNGX Comparison
SES vs TNGX Comparison
Compare SES & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- TNGX
- Stock Information
- Founded
- SES 2012
- TNGX 2014
- Country
- SES United States
- TNGX United States
- Employees
- SES N/A
- TNGX N/A
- Industry
- SES Auto Parts:O.E.M.
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SES Consumer Discretionary
- TNGX Health Care
- Exchange
- SES Nasdaq
- TNGX Nasdaq
- Market Cap
- SES 226.6M
- TNGX 248.2M
- IPO Year
- SES N/A
- TNGX N/A
- Fundamental
- Price
- SES $0.91
- TNGX $2.22
- Analyst Decision
- SES Hold
- TNGX Strong Buy
- Analyst Count
- SES 3
- TNGX 6
- Target Price
- SES $1.50
- TNGX $12.20
- AVG Volume (30 Days)
- SES 12.4M
- TNGX 3.5M
- Earning Date
- SES 04-24-2025
- TNGX 05-12-2025
- Dividend Yield
- SES N/A
- TNGX N/A
- EPS Growth
- SES N/A
- TNGX N/A
- EPS
- SES N/A
- TNGX N/A
- Revenue
- SES $7,833,000.00
- TNGX $40,990,000.00
- Revenue This Year
- SES $929.56
- TNGX N/A
- Revenue Next Year
- SES $140.44
- TNGX N/A
- P/E Ratio
- SES N/A
- TNGX N/A
- Revenue Growth
- SES N/A
- TNGX 10.09
- 52 Week Low
- SES $0.20
- TNGX $1.03
- 52 Week High
- SES $2.53
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- SES 53.38
- TNGX 62.75
- Support Level
- SES $0.91
- TNGX $1.93
- Resistance Level
- SES $1.01
- TNGX $2.67
- Average True Range (ATR)
- SES 0.08
- TNGX 0.40
- MACD
- SES -0.01
- TNGX 0.07
- Stochastic Oscillator
- SES 40.71
- TNGX 59.59
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.